What is Zoobiotic?
Zoobiotic, operating under the BioMonde umbrella, specializes in the development and distribution of larval therapy, a sophisticated method for natural wound debridement. By utilizing live larvae within sealed, sterile environments, the company provides a precise, non-invasive solution for cleaning infected or chronic wounds that are often resistant to conventional treatments. This innovative methodology not only improves patient quality of life but also reduces the burden on healthcare systems by accelerating the healing process.
The firm's market position is defined by its commitment to clinical excellence and expert product support. As a global leader in this niche biotech segment, Zoobiotic bridges the gap between historical medical practices and modern clinical requirements, fostering strong relationships with healthcare providers who seek reliable, evidence-based wound care solutions.
How much funding has Zoobiotic raised?
Zoobiotic has raised a total of $5.9M across 1 funding round:
Unspecified
$5.9M
Unspecified (2014): $5.9M with participation from Oxford Capital Partners and Finance Wales
Key Investors in Zoobiotic
Oxford Capital Partners
An investment manager focused on providing growth capital to smaller companies across diverse industries to help entrepreneurs scale their businesses.
Finance Wales
A development bank backed by the Welsh Government that provides equity finance and business loans to support economic growth and technology ventures.
What's next for Zoobiotic?
With the recent influx of capital, Zoobiotic is poised to scale its international operations and further refine its supply chain for larval therapy products. The strategic focus will likely shift toward increasing market penetration in key healthcare regions and investing in clinical research to validate the long-term efficacy of its debridement solutions. By leveraging its established relationships with practitioners, the company aims to standardize larval therapy as a primary intervention for complex wound management.
Furthermore, the company is expected to explore new product iterations that enhance the ease of application for clinicians, thereby driving adoption rates. As Zoobiotic continues to navigate the complexities of the biotech landscape, its focus on sustainable growth and patient outcomes will remain the primary driver of its long-term value proposition.
